NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.


Don't have an account? Subscribe

Lack of ‘single candidate biomarker’ a challenge in ARDS

By Mindo - 04th Dec 2019

Prof John Laffey of NUI Galway presented a talk on acute lung injury and acute respiratory distress syndrome (ARDS), at the recent ITS scientific meeting at the Galmont Hotel, Galway.

Histologically ARDS is an acute, inflammatory condition.

“One big problem we have is it’s a syndrome diagnosis. It’s basically a constellation of findings,” said Prof Laffey, who is a Professor of Anaesthesia and Intensive Care Medicine.

Prof John Laffey

The Berlin definition is the one currently used, and is an improvement, he added.

This definition states that acute onset is within one week of a known clinical insult or new/worsening respiratory syndrome. It also subdivides patients into three groups based on the degree of hypoxia.

“The problem is there is no definitive test. It is quite difficult to recognise in a critically ill patient,” he said.

There is a lot of work being carried out on how to improve the diagnostic criteria and investigations into biomarkers.

“But the bottom line is we don’t have a single candidate biomarker,” he said.

“We are making progress in terms of panels of biomarkers and integrating that with other findings. But we don’t have a good single candidate at this point.”

In terms of muscle relaxants, Prof Laffey told colleagues they are used on patients who are proving difficult to ventilate.

Regarding extracorporeal membrane oxygenation (ECMO) he said the data is flawed.

“But it is probably as good as it’s going to get,” he said.

He recommended that patients be referred early for ECMO.

“It’s got to be in the first two-to-three days. If you wait beyond that you are not going to see a benefit. The mechanic ventilation injury will have established itself and outcomes are much worse,” he said.

“So early referrals are critical.”

Future studies need to be done better, he said.

“We have done a huge amount of research but we have lumped a lot of patients together that are very different.

“Everyone in this room knows that an 85-year-old with CAP is very, very different to a 23-year-old with pancreatitis. And yet we both say they have ARDS because they fulfill clinical criteria.

“We have got to break these patients down into more physiological, and biologically homogeneous subgroups, and then test strategies on them.”

He said clinicians need to move towards personalised medicine.

Leave a Reply

Latest
Latest Issue
The Medical Independent 20th February 2024

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read